Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.40
- Piotroski Score 5.00
- Grade Overweight
- Symbol (TEVA)
- Company Teva Pharmaceutical Industries Limited
- Price $17.51
- Changes Percentage (0.43%)
- Change $0.08
- Day Low $17.43
- Day High $17.86
- Year High $19.31
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
- Last Earnings 11/02/2017
- Ex-Dividend for 5/16 Dividend 11/27/2017
- Dividend Payable 12/12/2017
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $22.00
- High Stock Price Target $26.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.42
- Trailing P/E Ratio -40.05
- Forward P/E Ratio -40.05
- P/E Growth -40.05
- Net Income $-559,000,000
Income Statement
Quarterly
Annual
Latest News of TEVA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ...
Teva can benefit from US-made generics push and expects positive safety label for olanzapine LAI. Strong 2025 outlook for US generics and UZEDY patients from oral medications. TAPI divestment on track...
By Yahoo! Finance | 20 hours ago -
Corteva reports larger-than-expected loss on low demand and pricing
Corteva, a U.S. agrichemicals company, reported a larger loss than expected due to reduced sales and prices. The company cut its full-year sales outlook due to decreased demand for crop chemicals, imp...
By Yahoo! Finance | 1 day ago -
Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript
Teva Pharmaceuticals reported strong performance in Q3 2024. The company is focused on growth strategies with innovative products like AUSTEDO, AJOVY, and UZEDY. Progress in the pipeline includes Phas...
By Yahoo! Finance | 1 day ago
